Genesis Biotechnology Group snaps up NEDP to boost its CRO work

petri dishes in a lab
Genesis Drug Discovery & Development's purchase of New England Discovery Partners comes after the company bought another CRO, NexusPharma, back in the summer. (science photo/Shutterstock)

Genesis Drug Discovery & Development (GD3) has bought up New England Discovery Partners (NEDP) as it looks to boost its synthetic and medicinal chemistry offerings.

The CRO acquisition, financial details of which were not released, also helps GD3 enhance its preclinical drug research and discovery services to its pharma and academia clients.

“NEDP's skilled team of chemists, with almost 250 years of combined pharma and CRO experience, will work synergistically with GD3's existing services around uHTS, computational chemistry, and structural biology,” the company said in a statement.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“We’re committed to building an industry-leading, fully integrated drug discovery CRO,” said Eli Mordechai, Ph.D., CEO of Genesis Biotechnology Group. “Adding NEDP is another way to differentiate our capabilities in the early drug discovery space. We're significantly enhancing our portfolio around organic and medical chemistry to better serve our industry partners.”

This comes after the company bought another CRO, NexusPharma, back in the summer.

That deal saw GD3 integrate the company’s collection of patient-derived xenograft models, with a focus on personalized medicine, including models for acquired resistance to targeted therapies.

Suggested Articles

The FDA warned healthcare providers about cybersecurity vulnerabilities within certain clinical information systems made by GE Healthcare.

Weeks after receiving FDA approval for its in-office eardrum tube device, Tusker Medical has been picked up by Smith & Nephew for an undisclosed sum.

What a difference a day makes in biotech.